ProQR Therapeutics' (PRQR) Market Outperform Rating Reiterated at JMP Securities

ProQR Therapeutics (NASDAQ:PRQR - Get Free Report)'s stock had its "market outperform" rating reissued by investment analysts at JMP Securities in a research note issued on Friday,Benzinga reports. They presently have a $8.00 price target on the biopharmaceutical company's stock. JMP Securities' target price points to a potential upside of 270.37% from the company's previous close.

Several other research analysts also recently commented on PRQR. Evercore ISI assumed coverage on shares of ProQR Therapeutics in a report on Tuesday, April 29th. They set an "outperform" rating and a $5.00 price objective for the company. Oppenheimer dropped their price target on ProQR Therapeutics from $15.00 to $9.00 and set an "outperform" rating for the company in a research note on Tuesday, May 13th. HC Wainwright raised their price target on ProQR Therapeutics from $10.00 to $12.00 and gave the company a "buy" rating in a report on Friday, March 14th. Citigroup raised ProQR Therapeutics from a "neutral" rating to a "buy" rating and set a $4.00 price objective on the stock in a research note on Monday, March 10th. Finally, Chardan Capital reiterated a "buy" rating and set a $4.00 target price on shares of ProQR Therapeutics in a research report on Friday, March 14th. One investment analyst has rated the stock with a sell rating, seven have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $8.00.

ProQR Therapeutics Price Performance

Shares of PRQR opened at $2.16 on Friday. The firm has a market cap of $227.25 million, a P/E ratio of -6.17 and a beta of 0.31. ProQR Therapeutics has a 1 year low of $1.07 and a 1 year high of $4.62. The company has a 50 day simple moving average of $1.72 and a two-hundred day simple moving average of $1.98.

ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) last issued its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing analysts' consensus estimates of ($0.09) by ($0.02). The company had revenue of $4.89 million for the quarter, compared to the consensus estimate of $4.90 million. ProQR Therapeutics had a negative return on equity of 53.49% and a negative net margin of 157.04%. On average, sell-side analysts anticipate that ProQR Therapeutics will post -0.31 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Jane Street Group LLC bought a new stake in ProQR Therapeutics during the fourth quarter worth approximately $30,000. Invesco Ltd. bought a new position in shares of ProQR Therapeutics during the 4th quarter valued at approximately $32,000. Alpine Global Management LLC bought a new position in shares of ProQR Therapeutics during the 4th quarter valued at approximately $39,000. Two Sigma Securities LLC purchased a new stake in ProQR Therapeutics during the 4th quarter valued at $40,000. Finally, Vontobel Holding Ltd. bought a new stake in ProQR Therapeutics in the first quarter worth $48,000. Hedge funds and other institutional investors own 32.65% of the company's stock.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.